Tracking Antigen-Specific T-Cells during Clinical Tolerance Induction in Humans
Open Access
- 9 June 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (6), e11028
- https://doi.org/10.1371/journal.pone.0011028
Abstract
Allergen immunotherapy presents an opportunity to define mechanisms of induction of clinical tolerance in humans. Significant progress has been made in our understanding of changes in T cell responses during immunotherapy, but existing work has largely been based on functional T cell assays. HLA-peptide-tetrameric complexes allow the tracking of antigen-specific T-cell populations based on the presence of specific T-cell receptors and when combined with functional assays allow a closer assessment of the potential roles of T-cell anergy and clonotype evolution. We sought to develop tools to facilitate tracking of antigen-specific T-cell populations during wasp-venom immunotherapy in people with wasp-venom allergy. We first defined dominant immunogenic regions within Ves v 5, a constituent of wasp venom that is known to represent a target antigen for T-cells. We next identified HLA-DRB1*1501 restricted epitopes and used HLA class II tetrameric complexes alongside cytokine responses to Ves v 5 to track T-cell responses during immunotherapy. In contrast to previous reports, we show that there was a significant initial induction of IL-4 producing antigen-specific T-cells within the first 3–5 weeks of immunotherapy which was followed by reduction of circulating effector antigen-specific T-cells despite escalation of wasp-venom dosage. However, there was sustained induction of IL-10-producing and FOXP3 positive antigen-specific T cells. We observed that these IL-10 producing cells could share a common precursor with IL-4-producing T cells specific for the same epitope. Clinical tolerance induction in humans is associated with dynamic changes in frequencies of antigen-specific T-cells, with a marked loss of IL-4-producing T-cells and the acquisition of IL-10-producing and FOXP3-positive antigen-specific CD4+ T-cells that can derive from a common shared precursor to pre-treatment effector T-cells. The development of new approaches to track antigen specific T-cell responses during immunotherapy can provide novel insights into mechanisms of tolerance induction in humans and identify new potential treatment targets.Keywords
This publication has 78 references indexed in Scilit:
- In vivo switch to IL-10–secreting T regulatory cells in high dose allergen exposureThe Journal of Experimental Medicine, 2008
- Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donorsClinical and Experimental Immunology, 2008
- Bacterial superantigen facilitates epithelial presentation of allergen to T helper 2 cellsProceedings of the National Academy of Sciences, 2007
- T Cell Epitope Immunotherapy Induces a CD4+ T Cell Population with Regulatory ActivityPLoS Medicine, 2005
- Fel d 1‐derived T cell peptide therapy induces recruitment of CD4+CD25+; CD4+ interferon‐γ+ T helper type 1 cells to sites of allergen‐induced late‐phase skin reactions in cat‐allergic subjectsClinical and Experimental Allergy, 2005
- Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+ CD25+ T cells: a double‐blind placebo‐controlled studyAllergy, 2004
- IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapyEuropean Journal of Immunology, 2003
- Effects of peptide therapy on ex vivo T-cell responsesJournal of Allergy and Clinical Immunology, 1998
- Generation of suppressor cells in atopic patients during immunotherapy that modulate IgE synthesisJournal of Allergy and Clinical Immunology, 1987
- Generation of Antigen-Specific Suppressor Cells during Allergy DesensitizationNew England Journal of Medicine, 1980